Clinical Trials
101 trialsTretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
N01-A-PICIT-GI
Peking University People's Hospital
N01-A-PICIT-GT
Peking University People's Hospital
LYSARI
Centre Leon Berard
QUATRO-APL
Quetzal Therapeutics
ATRA
The Methodist Hospital Research Institute
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
FACE
University of Utah
ATARI-PDAC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
STARPAC2
Queen Mary University of London
LATITUDE
SDK Therapeutics, Inc.
ATRA
Mario Negri Institute for Pharmacological Research
LySATRA
Gustave Roussy, Cancer Campus, Grand Paris
Resilire
Fudan University
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
KEYMAKER-U02
Merck Sharp & Dohme LLC
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Anhui Medical University
KEYMAKER-U02
Merck Sharp & Dohme LLC
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
University of Texas Southwestern Medical Center
TUD-APOLLO-064
Technische Universität Dresden
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
The First Affiliated Hospital of Xiamen University
A Study of TAS1440 With ATRA in Subjects With r/r AML
Taiho Oncology, Inc.
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
Ruijin Hospital
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
China Medical University Hospital
Optimum Induction Therapy of Low-risk APL
Peking University People's Hospital
AML-ViVA
University Hospital Regensburg
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
IMG-7289-CTP-101
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome
Eastern Cooperative Oncology Group
DARA/ATRA
Amsterdam UMC, location VUmc
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
Dana-Farber Cancer Institute
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
SWOG Cancer Research Network
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
NB2013-HR
University of Cologne
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Children's Oncology Group
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
The University of Hong Kong
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
First Affiliated Hospital Xi'an Jiaotong University
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
The First Affiliated Hospital of Soochow University
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
APL16
First Affiliated Hospital Xi'an Jiaotong University